Testing Lifespan/Healthspan-Extension Interventions in the Models of Alzheimers Disease (AD/ADRD) (R43/R44 Clinical Trial Not Allowed)

Funding Opportunity PAR-18-512 from the NIH Guide for Grants and Contracts. This funding opportunity (FOA) encourages small business-based (SBIR) research and development of commercial pharmaceutical interventions to extend lifespan and/or healthspan, to prevent, treat, and/or slow the progression of symptoms associated with Alzheimer's disease (AD) and Alzheimer's disease related dementia (ADRD) in human cells and/or tissue, in-vitro models, and/or non-human animals.
Source: NIH Funding Opportunities (Notices, PA, RFA) - Category: Research Source Type: funding